| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
25052 |
| Drug |
Blinatumomab |
| Brand |
Blincyto® |
| Indication |
Blinatumomab (Blincyto®) is indicated as monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia. |
| Rapid review commissioned |
20/08/2025 |
| Rapid review completed |
12/09/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of blinatumomab for this indication compared with the current standard of care. |
| Full HTA commissioned by the HSE |
01/10/2025 |
| Pre-submission consultation with Applicant |
05/11/2025 |
